1 January 2009 in European Urology
1 June 2015 in European Urology
1 March 2002 in Journal of Urology
1 August 2013 in Journal of Urology
The purpose of this guideline is to provide a clinical framework for follow-up of clinically localized renal neoplasms undergoing active surveillance, or following definitive therapy. A systematic literature review identified published articles in the English literature between January 1999 and 2011 relevant to key questions specified by the Panel related to kidney neoplasms and their follow-up (imaging, renal function, markers, biopsy, prognosis). Study designs consisting of clinical trials (randomized or not), observational studies (cohort, case-control, case series) and systematic reviews were included. Guideline statements provided guidance for ongoing evaluation of renal function, usefulness of renal biopsy, timing/type of radiographic imaging and formulation of future research initiatives. A lack of studies precluded risk stratification beyond tumor staging; therefore, for the purposes of postoperative surveillance guidelines, patients with localized renal cancers were grouped into strata of low- and moderate- to high-risk for disease recurrence based on pathological tumor stage. Evaluation for patients on active surveillance and following definitive therapy for renal neoplasms should include physical examination, renal function, serum studies and imaging and should be tailored according to recurrence risk, comorbidities and monitoring for treatment sequelae. Expert opinion determined a judicious course of monitoring/surveillance that may change in intensity as surgical/ablative therapies evolve, renal biopsy accuracy improves and more long-term follow-up data are collected. The beneficial impact of careful follow-up will also need critical evaluation as further study is completed.
17 October 2008 in Cancer
BACKGROUND.: Neoadjuvant cisplatin‐based chemotherapy improves survival in muscle‐invasive urothelial cancer, with MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) considered the standard regimen. Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment.METHODS.: The authors retrospectively evaluated patients with muscle‐invasive urothelial carcinoma who received neoadjuvant GC before radical cystectomy between November 2000 and December 2006 at Memorial Sloan‐Kettering Cancer Center. Post‐therapy pathological downstaging to either residual disease at cystectomy (pT0) or no residual muscle‐invasion (<pT2, ie, pT0, pTIS, pT1), chemotherapy delivery, and disease‐free survival were the endpoints of interest. For comparison, similar endpoints were assessed in a historical cohort treated with neoadjuvant MVAC.RESULTS.: Four cycles of neoadjuvant GC were given over 12 weeks (n = 42). Thirty‐nine (93%) of 42 patients received 4 cycles, with a median 91% drug delivery for cisplatin and 90% for gemcitabine. The pT0 proportion was 26% (95% confidence interval [CI], 14‐42), and no residual muscle‐invasive disease proportion (<pT2) was 36% (95% CI, 21‐52); pT0 was achieved in 28% (95% CI, 16‐42) and <pT2 in 35% (95% CI, 23‐49) of 54 MVAC‐treated patients. All 15 GC patients achieving <pT2 pathologic stage remained disease‐free at a median follow‐up of 30 months.CONCLUSIONS.: Neoadjuvant GC is feasible and allows for timely drug delivery. The proportion of GC‐treated patients whose primary tumors were downstaged, with prolonged disease‐free survival and minimal or no residual disease, was similar to MVAC‐treated patients. Cancer 2008. © 2008 American Cancer Society.